Expressversand auf die Halbinsel
Here are 8 potential reasons why not to prescribe Lixisenatide: 1- this is only one small study and only one dose was tested, 2- Lixisenatide is not currently available at pharmacies, 3- the weight loss associated with this GLP-1 is not desirable in many cases of Parkinsons disease where weight loss is an issue, 4- non-motor outcomes did not change as in other trials, and this will need to be better explained
They represent the first time in the pharmacological history of obesity treatment that a drug trial has produced bariatric-surgery-level weight reduction at this scale, across 2,339 participants
Answer: Retatrutide trials focus on adults with obesity or overweight, typically a BMI at or above 27, who also carry a weight-related condition such as type 2 diabetes, pre-diabetes, high blood pressure, or high cholesterol